Modality
Small Molecule
MOA
EZH2i
Target
RET
Pathway
Checkpoint
ALLRett
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Sep 2029
Phase 1Current
NCT03023625
2,003 pts·ALL
2017-05→2029-09·Not yet recruiting
2,003 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-103.4y awayPh2 Data· ALL
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2029-09-10 · 3.4y away
ALL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03023625 | Phase 1/2 | ALL | Not yet recr... | 2003 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF |